戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tations of TTR such as L55P (associated with familial amyloid polyneuropathy).
2 00 mutations in the TTR gene are involved in familial amyloid polyneuropathy.
3  as Alzheimer's and Parkinson's diseases and familial amyloid polyneuropathy.
4  a useful prognostic marker in transthyretin familial amyloid polyneuropathy.
5 on detected by MIBG imaging in transthyretin familial amyloid polyneuropathy.
6 ly the only medication approved to treat TTR familial amyloid polyneuropathy.
7 ing, while several TTR mutants are linked to familial amyloid polyneuropathy.
8 tively cause senile systemic amyloidosis and familial amyloid polyneuropathy.
9 the course of senile systemic amyloidosis or familial amyloid polyneuropathy.
10 the diseases senile systemic amyloidosis and familial amyloid polyneuropathy.
11 nsidered part of the syndrome of TTR-related familial amyloid polyneuropathy.
12 ibits the amyloidogenesis of the most common familial amyloid polyneuropathy and familial amyloid car
13 ween TTR amyloid deposition and the onset of familial amyloid polyneuropathy and senile systemic amyl
14 fibril formation is observed systemically in familial amyloid polyneuropathy and senile systemic amyl
15 e, transthyretin V30M mutant associated with familial amyloid polyneuropathy, and Abeta42 associated
16 yloid diseases: senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid ca
17 associated with senile systemic amyloidosis, familial amyloid polyneuropathy, and familial amyloid ca
18 oid diseases, including Alzheimer's disease, familial amyloid polyneuropathy, and senile systemic amy
19 opic hepatic transplantation is effective in familial amyloid polyneuropathy associated with variant
20                 The L55P transthyretin (TTR) familial amyloid polyneuropathy-associated variant is di
21 eripheral nervous system which characterizes familial amyloid polyneuropathy caused by variant TTR.
22             Interestingly, the L55P and V30M familial amyloid polyneuropathy (FAP) associated variant
23                                              Familial amyloid polyneuropathy (FAP) associated with mu
24 Autonomic neuropathy is a major component of familial amyloid polyneuropathy (FAP) due to mutated tra
25                                              Familial amyloid polyneuropathy (FAP) is a neurodegenera
26                  Transthyretin (TTR)-related familial amyloid polyneuropathy (FAP) is an autosomal do
27 sthyretin gene (TTR) in Indian patients with familial amyloid polyneuropathy (FAP) is described.
28 ino liver transplant in which a patient with familial amyloid polyneuropathy (FAP) received an orthot
29 utonomic symptoms are early presentations of familial amyloid polyneuropathy (FAP) with transthyretin
30                           In the most common familial amyloid polyneuropathy (FAP), transthyretin (TT
31 he clinical status of patients with V30M TTR familial amyloid polyneuropathy (FAP), we quantified pla
32 ansthyretin (senile systemic amyloidosis and familial amyloid polyneuropathy), immunoglobulin light c
33  TTR mutation is the most prevalent cause of familial amyloid polyneuropathy in heterozygotes, wherea
34                                Transthyretin familial amyloid polyneuropathy is a hereditary form of
35 at tolcapone, already in clinical trials for familial amyloid polyneuropathy, is a strong candidate f
36                                              Familial amyloid polyneuropathy may respond to liver tra
37           The most common example is that of familial amyloid polyneuropathy, of particular concern f
38 loid diseases senile systemic amyloidosis or familial amyloid polyneuropathy, respectively.
39                             At month 24, the familial amyloid polyneuropathy stage and polyneuropathy
40 Secondary end points included changes in the familial amyloid polyneuropathy stage, polyneuropathy di
41 an Medicines Agency for the treatment of TTR familial amyloid polyneuropathy, the most common familia
42 elay neurologic progression of transthyretin familial amyloid polyneuropathy, there are no approved p
43 ials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-FAP) and demonstrat
44 FN) is an important feature of transthyretin familial amyloid polyneuropathy (TTR-FAP).
45                                              Familial amyloid polyneuropathy type I is an autosomal d
46  presentations of the disease: transthyretin familial amyloid polyneuropathy, which primarily affects
47  ATTR patients after LTx, as reported to the Familial Amyloid Polyneuropathy World Transplant Registr